Evidence map›Paper›PMID 41810969›Full record

ArticleAntimicrobial agents and chemotherapy2026

Stepwise evolution and clonal enrichment of gepotidacin resistance in

Linxin Yao, Tingli Tian, Danyang Zou, Xinying Lu, Nanyan Jiang, Xin Feng, Tong Zheng, Zhuojun Tang, Yi Lin, Zhen Ning and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Linxin Yao *STD Institute, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.ORCID 0009-0005-4961-7698
Tingli Tian *STD Institute, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Danyang ZouSTD Institute, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Xinying LuDepartment of Dermatology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Nanyan JiangDepartment of Dermatology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xin FengSTD Institute, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Tong ZhengSTD Institute, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
Zhuojun TangDepartment of Dermatology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yi LinDivision of Tuberculosis and HIV/AIDS Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
Zhen NingDivision of Tuberculosis and HIV/AIDS Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
Jianping JiangInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-1066-6362
Meiping YeSTD Institute, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.ORCID 0009-0006-3036-1845
Pingyu ZhouSTD Institute, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.ORCID 0000-0002-9623-4201

Funding

National Natural Science Foundation of China 82072322National Natural Science Foundation of China 82172319National Natural Science Foundation of China 82572581Natural Science Foundation of Shanghai 25ZR1401040
6 · The paper itself

Abstract

Although gepotidacin is a promising oral candidate for treating multidrug-resistant

Indexed as

Anti-Bacterial AgentsNeisseria gonorrhoeaeAcenaphthenesChinaDNA GyraseDNA Topoisomerase IVDrug Resistance, BacterialDrug Resistance, Multiple, BacterialGonorrheaHeterocyclic Compounds, 3-RingHumansMicrobial Sensitivity TestsMutationAcenaphthenesAnti-Bacterial AgentsDNA GyraseDNA Topoisomerase IVgepotidacinHeterocyclic Compounds, 3-Ringantimicrobial resistancegepotidacinNeisseria gonorrhoeaeParC D86Nstepwise evolution

Identifiers

PMID41810969
PMCPMC13041355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.